Chargement en cours...
Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in treatment‐naïve patients. We evaluated EFV400 and EFV600 pharmacokinetics (NONMEM v. 7.2), assessing patient demographics and genetic polymorphisms (CYP2B6, CYP2A6, CYP3A4, NR1I3) as covariates and explor...
Enregistré dans:
| Publié dans: | Clin Pharmacol Ther |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4744681/ https://ncbi.nlm.nih.gov/pubmed/26044067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.156 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|